传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LEGN 传奇生物

未开盘 02-12 16:00:00 EST

18.06

-0.48

-2.59%

盘后17.99

-0.07-0.39%

18:47 EST

最高18.67	最低17.91	成交量223.56万
今开18.05	昨收18.54	日振幅4.12%
总市值33.35亿	流通市值14.70亿	总股本1.85亿
成交额4,057万	换手率2.75%	流通股本8,138万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LEGN","market":"US","secType":"STK","nameCN":"传奇生物","latestPrice":18.06,"timestamp":1770930000000,"preClose":18.54,"halted":0,"volume":2235641,"hourTrading":{"tag":"盘后","latestPrice":17.99,"preClose":18.06,"latestTime":"18:47 EST","volume":17346,"amount":313199.33,"timestamp":1770940074111,"change":-0.07,"changeRate":-0.003876,"amplitude":0.00443},"delay":0,"changeRate":-0.02588996763754048,"floatShares":81382003,"shares":184689564,"eps":-1.30264,"marketStatus":"未开盘","change":-0.48,"latestTime":"02-12 16:00:00 EST","open":18.05,"high":18.67,"low":17.907,"amount":40573881.684137,"amplitude":0.041154,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.30264,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770973200000},"marketStatusCode":0,"adr":0,"adrRate":2,"listingDate":1591329600000,"exchange":"NASDAQ","adjPreClose":18.54,"preHourTrading":{"tag":"盘前","latestPrice":18.2,"preClose":18.54,"latestTime":"09:25 EST","volume":3382,"amount":62214.66324,"timestamp":1770906300010,"change":-0.34,"changeRate":-0.018339,"amplitude":0.016181},"postHourTrading":{"tag":"盘后","latestPrice":17.99,"preClose":18.06,"latestTime":"18:47 EST","volume":17346,"amount":313199.33,"timestamp":1770940074111,"change":-0.07,"changeRate":-0.003876,"amplitude":0.00443},"volumeRatio":0.708504,"impliedVol":0.5504,"impliedVolPercentile":0.488},"requestUrl":"/m/hq/s/LEGN/wiki","defaultTab":"wiki","newsList":[{"id":"2606925154","title":"金斯瑞生物科技：传奇生物任命孟建革为董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2606925154","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606925154?lang=zh_cn&edition=full","pubTime":"2026-01-25 16:08","pubTimestamp":1769328532,"startTime":"0","endTime":"0","summary":"1月23日，金斯瑞生物科技（01548）发布公告，宣布其联营公司传奇生物科技股份有限公司任命孟建革为董事，任期至2026年周年股东大会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601253629921412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","LEGN","HK0000306701.USD","BK1583","HK0000320223.HKD","01548","BK1576","BK4505","BK4585","HK0000306685.HKD","BK1141","HK0000320264.USD","BK4588"],"gpt_icon":0},{"id":"2605405308","title":"金斯瑞生物科技(01548)：孟建革获委任为传奇生物科技董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2605405308","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605405308?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:13","pubTimestamp":1769177619,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，自2026年1月20日起，传奇生物科技股份有限公司(“传奇”，为公司联营公司，其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)董事会任命孟建革先生为董事，初始任期至传奇2026年周年股东大会为止。孟建革先生获委任接替朱力博士于传奇董事会的职务，朱力博士于生效日期辞任该职务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","BK4139","BK4588","LEGN","HK0000306685.HKD","BK1141","01548","BK4505","HK0000320264.USD","BK1583","BK1576","HK0000320223.HKD","BK4585"],"gpt_icon":0},{"id":"2605446971","title":"终于有国产CAR-T企业快要扭亏了！传奇生物预计今年实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2605446971","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605446971?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:08","pubTimestamp":1769072934,"startTime":"0","endTime":"0","summary":"在绝大多数国产CAR-T企业苦于商业化挣扎之际，率先出海的传奇生物（LEGN.NS）业绩快要“上岸”了。传奇生物的CAR-T药物合作方强生于当地时间1月21日公布的财报显示，Carvykti（西达基奥仑赛）在2025年实现收入18.88亿美元，较上年同期（9.63亿美元）增长95.9%。西达基奥仑赛是一款用于治疗复发或难治性多发性骨髓瘤的细胞疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601223627442037.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627442037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4505","BK4588","LEGN","BK4230","CAR","BK4585","BK4139","BK4022"],"gpt_icon":0},{"id":"2605455188","title":"港股异动 | 金斯瑞生物科技(01548)跌超7% 联营传奇生物隔夜股价大跌逾11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605455188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605455188?lang=zh_cn&edition=full","pubTime":"2026-01-22 10:58","pubTimestamp":1769050689,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)跌超7%，截至发稿，跌6.98%，报13.07港元，成交额1.3亿港元。消息面上，金斯瑞生物科技联营传奇生物隔夜股价大跌逾11%。1月21日晚，金斯瑞生物科技公布，传奇生物披露CARVYKTI于截至去年12月31日止第四季度贸易销售净额约5.55亿美元。该集团指，贸易销售净额乃基于杨森向传奇提供的资料，传奇与该集团均未独立核实该销售数字的准确性。据了解，CARVYKTI前三季度实现销售额13.32亿美元，其中第三季度销售额为5.24亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","BK1610","BK1141","BK1583","HK0000306701.USD","LEGN","BK1576","HK0000306685.HKD","BK4139","BK4505","BK4585","BK4588","HK0000320264.USD","01548"],"gpt_icon":0},{"id":"2602031467","title":"前传奇生物副总裁潘琦加盟水木分子，出任生物医药首席科学家","url":"https://stock-news.laohu8.com/highlight/detail?id=2602031467","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602031467?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:39","pubTimestamp":1767919140,"startTime":"0","endTime":"0","summary":"新浪科技讯 1月9日上午消息，新浪科技独家获悉，原传奇生物研发副总裁潘琦已加入清华大学智能产业院 孵化成立的AI生物医药企业“水木分子”，将出任生物医药首席科学家全面负责公司生物医药与ChatDD科研战略、研发体系建设、AI 药物管线推进及全球合作布局等工作。　　据知情人士对新浪科技透露，加入水木分子前，潘琦近期曾任职于美国知名AI肿瘤生物技术公司Pathos，任癌症生物学高级副总裁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tob/2026-01-09/doc-inhfsfzv3104115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LEGN","BK4505","399441","161726","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2601879976","title":"股价半年即“腰斩”，传奇生物(LEGN.US)挖出的是估值陷阱还是黄金坑？","url":"https://stock-news.laohu8.com/highlight/detail?id=2601879976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601879976?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:47","pubTimestamp":1767779266,"startTime":"0","endTime":"0","summary":"1月6日，传奇生物股价在开盘5分钟内出现一波下探，虽然后续出现大幅反弹带动日内最高涨幅突破6%，但那波下探却将传奇生物在2026年的股价最低点定格在了20.21美元。但在11月12日，传奇生物在当日股价下跌2.67%的情况下出现前期明显的成交量放。目前来看，传奇生物的营收主要由许可收入和合作收入两部分构成。并且对比Carvykti在34个月的随访数据，Tec-Dara联合治疗组已经超越其的84.6%响应率和76.4%的OS率，且在残余病灶阴性率上与Carvykti保持一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4588","GCmain","IAU","LEGN","QOmain","DUST","MGCmain","BK4585","159831","GDX","BK4505","SGCmain","159934","SGUmain","1OZmain","NUGT","518880"],"gpt_icon":1},{"id":"2592838922","title":"体内CAR-T赛道白热化：盘点国内19家核心企业管线全景图","url":"https://stock-news.laohu8.com/highlight/detail?id=2592838922","media":"求实药社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592838922?lang=zh_cn&edition=full","pubTime":"2025-12-18 12:02","pubTimestamp":1766030559,"startTime":"0","endTime":"0","summary":"跨国药企重磅加注，国内Biotech加速推进，体内CAR-T已成细胞治疗领域的热门赛道。这项颠覆性技术旨在解决传统CAR-T高成本、长周期的痛点，并进一步拓展血液瘤、实体瘤及自免疾病适应症。纵观国内研发格局，体内CAR-T正呈现出“技术路线多元化”与“临床验证加速化”的双重特征。从进展来看，IIT已成为当前验证体内CAR-T安全性与有效性的主战场。2025年3月完成首例患者给药，进入临床阶段，是国内较早进入体内CAR临床阶段的企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218134128a459f8ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218134128a459f8ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","LEGN","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2590792392","title":"港股异动 | 金斯瑞生物科技(01548)午后跌幅扩大逾11% 联营传奇生物隔夜股价大跌7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590792392","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590792392?lang=zh_cn&edition=full","pubTime":"2025-12-09 13:53","pubTimestamp":1765259591,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技午后跌幅扩大逾11%，截至发稿，跌11.07%，报13.41港元，成交额3.07亿港元。消息面上，金斯瑞生物科技联营传奇生物隔夜股价大跌超7%，据媒体报道，在2025年美国血液学会 年会上，吉利德科学旗下 Kite Pharma 公布了下一代 CAR-T疗法 anito-cel 的最新临床数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","BK4588","HK0000320264.USD","HK0000320223.HKD","BK1576","BK4505","BK1141","BK1583","HK0000306685.HKD","BK4139","LEGN","BK4585","01548"],"gpt_icon":0},{"id":"1119581053","title":"传奇生物在2025年ASH大会上重点展示Carvykti®在多发性骨髓瘤的新数据及新型CAR-T平台在人类的首次应用结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119581053","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119581053?lang=zh_cn&edition=full","pubTime":"2025-12-07 03:01","pubTimestamp":1765047672,"startTime":"0","endTime":"0","summary":"传奇生物在2025年ASH大会上重点展示Carvykti®在多发性骨髓瘤的新数据及新型CAR-T平台在人类的首次应用结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LEGN","BK4585","BK4505","BK4588"],"gpt_icon":0},{"id":"2583753060","title":"港股异动 | 金斯瑞生物科技(01548)跌超4% 联营传奇生物三季度净亏损收窄至3970万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583753060","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583753060?lang=zh_cn&edition=full","pubTime":"2025-11-13 13:58","pubTimestamp":1763013530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)逆势跌超4%，截至发稿，跌4.25%，报16.43港元，成交额2.21亿港元。消息面上，11月12日晚，金斯瑞生物科技的的联营公司传奇生物披露截至2025年9月30日止第三季度财务业绩。财务数据显示，截至2025年9月30日止三个月的净亏损为3970万美元，去年同期净亏损为1.253亿美元；调整后净亏损为1880万美元，去年同期调整后净亏损为4200万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4139","HK0000320264.USD","01548","BK1576","BK4585","BK4505","BK1141","LEGN","HK0000306701.USD","HK0000306685.HKD","BK4588","HK0000320223.HKD"],"gpt_icon":0},{"id":"1127477547","title":"异动解读 | 传奇生物第三季度亏损收窄 股价仍盘中大跌6.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127477547","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127477547?lang=zh_cn&edition=full","pubTime":"2025-11-13 02:24","pubTimestamp":1762971868,"startTime":"0","endTime":"0","summary":"美国细胞疗法公司传奇生物周三盘中大跌6.46%，尽管公司第三季度财报显示亏损有所收窄。根据传奇生物公布的2025年第三季度未经审计财务报告，公司净亏损从去年同期的1.253亿美元收窄至3,970万美元。公司主打产品CARVYKTI的净销售额约为5.24亿美元，延续了强劲的环比增长势头。尽管财务状况有所改善，但市场对传奇生物的反应仍显谨慎。分析人士指出，虽然CARVYKTI销售强劲，但公司整体仍处于亏损状态，且研发费用持续上升。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LEGN"],"gpt_icon":0},{"id":"1131577985","title":"Synox Therapeutics增聘领先商业化及企业发展专家，进一步强化董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1131577985","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131577985?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:02","pubTimestamp":1761044561,"startTime":"0","endTime":"0","summary":"Synox Therapeutics增聘领先商业化及企业发展专家，进一步强化董事会，以继续推动公司的发展进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","EXEL","BK4585","BK4588","LEGN","AKRO","BK4505","BK4139"],"gpt_icon":0},{"id":"2575564209","title":"港股异动丨金斯瑞生物科技涨超4% 传奇生物旗下CAR-T产品第三季度销售额达5.24亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575564209","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575564209?lang=zh_cn&edition=full","pubTime":"2025-10-15 16:03","pubTimestamp":1760515381,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技(1548.HK)盘中涨4.71%至16.67港元，年内累涨近70%，跑赢大盘表现(同期恒指累涨约30%)。消息面上，金斯瑞生物科技宣布，传奇生物科技股份有限公司(为公司联营公司已于2025年10月14日(纽约时间)向美国证券交易委员会提交6-K表格，并宣布，根据传奇与Janssen Biotech, Inc.(杨森)于2017年12月21日订立的合作及许可协议，CARVYKTI®于截至2025年9月30日止季度产生贸易销售净额约5.24亿美元。(格隆汇)\n\n\r\n            责任编辑：山上","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/10/15160353635849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HK0000320264.USD","BK4505","BK1583","01548","CAR","HK0000320223.HKD","BK4230","BK4588","BK4139","BK4022","BK4585","HK0000306685.HKD","BK1141","LEGN","HK0000306701.USD","BK1576"],"gpt_icon":0},{"id":"1129494241","title":"传奇生物：Carvykti在截至2025年9月30日的季度内实现净贸易销售额约5.24亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129494241","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129494241?lang=zh_cn&edition=full","pubTime":"2025-10-14 19:35","pubTimestamp":1760441718,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会提交的文件显示，传奇生物旗下产品Carvykti在截至2025年9月30日的第三季度内，实现净贸易销售额约5.24亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","BK4139","BK4588","BK4505","BK4585"],"gpt_icon":0},{"id":"1134616559","title":"传奇生物：Janssen将基于Cilta-Cel生产供应总成本加指定加价进行转移定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1134616559","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134616559?lang=zh_cn&edition=full","pubTime":"2025-10-08 04:10","pubTimestamp":1759867834,"startTime":"0","endTime":"0","summary":"传奇生物宣布，Janssen将根据Cilta-Cel的生产和供应总成本，加上指定的加价幅度来确定转移价格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","BK4588","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"1163365168","title":"传奇生物：美国子公司与Janssen Pharmaceuticals签署组件及产品供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1163365168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163365168?lang=zh_cn&edition=full","pubTime":"2025-10-08 04:06","pubTimestamp":1759867586,"startTime":"0","endTime":"0","summary":"传奇生物宣布，其美国子公司传奇生物美国有限公司已与Janssen Pharmaceuticals, Inc.签署组件和产品供应协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","BK4505","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2570035010","title":"创新药寻突围，“自研+引入”双轨战略能否重塑增长极？","url":"https://stock-news.laohu8.com/highlight/detail?id=2570035010","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570035010?lang=zh_cn&edition=full","pubTime":"2025-09-26 12:59","pubTimestamp":1758862756,"startTime":"0","endTime":"0","summary":"与此同时，2025年第二季度中国创新药对外BD首付款金额高达17.3亿美元，远超同期中国生物医药投融资金额6.9亿美元。根据药智网公布的数据，创新药从临床试验Ⅰ期到批准上市的可能性为12.69%，而整体研发成功率则更低。BD合作已成为创新药研发投入的新资金来源和主要资金来源。柳丹指出，未盈利创新药企需多元融资保障生存。今年上半年全球医药交易TOP10中，中国创新药资产的贡献率超过80%，且交易金额最高的资产也来自国内药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926130238a4450c27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","02142","LEGN","BK4505","BK4139","ORR"],"gpt_icon":0},{"id":"2570802615","title":"鬼故事不一定能落地，但投资者的逻辑也应该慢慢变了","url":"https://stock-news.laohu8.com/highlight/detail?id=2570802615","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570802615?lang=zh_cn&edition=full","pubTime":"2025-09-26 07:28","pubTimestamp":1758842910,"startTime":"0","endTime":"0","summary":"创新药的鬼故事不一定能落地，但投资者却应该提前做好医药投资逻辑切换的准备。也就是说，虽然BD依然可以给药企带来诸多益处，但终有一天投资者会不再以BD作为交易决策的核心逻辑。“BD为王”的逻辑注定会逐渐淡化，并且在投资者的争议之中找到新的投资主线。所以投资者对于BD的关注应该适当降温，并做好达成新共识的准备。从研发预期，向商业化成绩落地，这将是中国创新药投资的大趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926073037a4446495&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926073037a4446495&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1574","LU0359202008.SGD","02142","09688","LU0359201885.HKD","BK1161","06855","LEGN","LU0359201612.USD","02269","09995","09969","01952","06618","BK1191","01276","LU1023057109.AUD","02096","LU2543165471.USD","01801","06978"],"gpt_icon":1},{"id":"2569229688","title":"近两个月股价最大跌幅达25%，二次上市会是传奇生物(LEGN.US)股价反弹良方？","url":"https://stock-news.laohu8.com/highlight/detail?id=2569229688","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569229688?lang=zh_cn&edition=full","pubTime":"2025-09-21 20:14","pubTimestamp":1758456864,"startTime":"0","endTime":"0","summary":"今年9月5日，彭博社援引知情人士消息称，由于投资者对制药商表现出浓厚兴趣，传奇生物正考虑在美国以外进行二次上市。在二次上市传闻披露后，传奇生物股价在9月8日至10日依旧走出“三连跌”，随后股价在低位波动。9月19日，公司收盘价34.01美元，近两个月股价最大跌幅已达25%。5月14日，传奇生物股价大跌10.55%，并在次日触及27.43美元低点，创下自2021年5月以来的股价新低。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","BK4139","LEGN","BK4585","BK4505"],"gpt_icon":0},{"id":"2566921919","title":"美股异动 | 中概医药股上涨 再鼎医药(ZLAB.US)涨超14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566921919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566921919?lang=zh_cn&edition=full","pubTime":"2025-09-11 22:41","pubTimestamp":1757601703,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0239","06978","LU0061475181.USD","LU1969619763.USD","LU1791807156.HKD","BK1587","LU1668664300.SGD","BK4505","BK1191","159992","LU1868837300.USD","HCM","LU0742534661.SGD","LU0048573561.USD","09939","BK4516","LU1868837136.USD","ZLAB","LU1868836591.USD","09688","06160","IE00B19Z3581.USD","BK4531","00013","BK4526","BK4139","LU1894683264.USD","LU2237443895.HKD","LU1868836914.USD","BK1515","ONC","LU2237443465.HKD","159938","LU1303224171.USD","IE0004091025.USD","BK1500","BK1574","LU0096364046.USD","LU1894683348.USD","688235","BK4550","LU2237443978.SGD","BK4007","LU2328871848.SGD","LEGN","LU0106831901.USD","BK4552","IE00BFXG1179.USD","LU0251142724.SGD","LU2471134796.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.legendbiotech.com","stockEarnings":[{"period":"1week","weight":0.0814},{"period":"1month","weight":-0.1998},{"period":"3month","weight":-0.4038},{"period":"6month","weight":-0.5184},{"period":"1year","weight":-0.4965},{"period":"ytd","weight":-0.1693}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"传奇生物科技有限公司是一家全球性的临床级生物制药公司，致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.047546},{"month":2,"riseRate":0.5,"avgChangeRate":0.008807},{"month":3,"riseRate":0.4,"avgChangeRate":-0.028053},{"month":4,"riseRate":0.8,"avgChangeRate":0.075373},{"month":5,"riseRate":0.4,"avgChangeRate":0.007649},{"month":6,"riseRate":1,"avgChangeRate":0.150366},{"month":7,"riseRate":0.666667,"avgChangeRate":0.033873},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.05555},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.023313},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.000245},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.020911},{"month":12,"riseRate":0,"avgChangeRate":-0.105244}],"exchange":"NASDAQ","name":"传奇生物","nameEN":"Legend Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"传奇生物,LEGN,传奇生物股票,传奇生物股票老虎,传奇生物股票老虎国际,传奇生物行情,传奇生物股票行情,传奇生物股价,传奇生物股市,传奇生物股票价格,传奇生物股票交易,传奇生物股票购买,传奇生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}